Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction

NCT01920711 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

4822

Enrollment

INDUSTRY

Sponsor class

Conditions

Heart Failure With Preserved Ejection Fraction

Interventions

DRUG: LCZ696
DRUG: Valsartan

Sponsor

Novartis Pharmaceuticals